| Literature DB >> 30847774 |
Nana Arai1,2, Mayumi Homma3, Maasa Abe4, Yuta Baba4, So Murai4, Megumi Watanuki4, Yukiko Kawaguchi4, Shun Fujiwara4, Nobuyuki Kabasawa4, Hiroyuki Tsukamoto4, Yui Uto4, Hirotsugu Ariizumi4, Kouji Yanagisawa4, Norimichi Hattori4, Bungo Saito4, Eisuke Shiozawa3, Hiroshi Harada5, Toshiko Yamochi-Onizuka3, Tsuyoshi Nakamaki4, Masafumi Takimoto3.
Abstract
Aberrant expression of the interleukin-3 receptor alpha chain (IL3RA or CD123) is frequently observed in patients with a subset of leukemic disorders, including acute myeloid leukemia (AML), particularly in leukemia stem cells. We analyzed the relationships between immunohistochemical (IHC) expression, including that of CD123, and clinical outcomes. This study involved a retrospective analysis of 48 patients diagnosed with de novo AML (M0-M5, n = 48) at our hospital between February 2008 and September 2015. Among patients with de novo AML, CD123 expression was associated with a failure to achieve complete response (CR) to initial induction chemotherapy (P = 0.044) and poor overall survival (OS) (P = 0.036). This is the first study using IHC to demonstrate that CD123 expression is associated with a poor CR rate and poor OS in de novo AML patients. These results support previous reports using flow cytometry (FCM). CD123 expression may thus be useful for assessing AML patients' prognoses. At the time of diagnosis, CD123 expression analysis using IHC may represent a clinically useful assessment for de novo AML patients.Entities:
Keywords: Acute myeloid leukemia; CD123 expression; Immunohistochemistry (IHC); P53 expression
Mesh：
Substances：
Year: 2019 PMID： 30847774 DOI： 10.1007/s12185-019-02616-y
Source DB: PubMed Journal: Int J Hematol ISSN： 0925-5710 Impact factor: 2.490